Arvinas registers first-in-human Phase 1/2 trial of ARV-6723 in advanced solid tumors

Arvinas' registry activity for the week centers on a single new trial listing for its investigational compound ARV-6723.

• ARV-6723, an oral tablet, is being tested in a Phase 1/2 study for participants with advanced solid tumors, with the trial listed as recruiting and an actual start date of 2026-07-29. The study is sponsored by Arvinas Inc.¹ The company said it believes ARV-6723 may help the immune system better recognize and attack cancer cells, and the trial marks the compound's first use in humans.¹
• The design includes dosing of ARV-6723 alone and combined with pembrolizumab, given by IV or subcutaneous injection. Depending on treatment assignment, participants will receive ARV-6723 as an oral tablet either on its own or alongside pembrolizumab administered intravenously or subcutaneously.¹
• The protocol is structured in stages, moving from initial dose-finding work toward expansion in specific tumor types. An early phase (Part A1) will test a range of ARV-6723 doses alone or with standard-dose pembrolizumab in small groups; a later phase (Part A2) will select two doses for testing in specific tumor indications still to be determined, and a further stage (Part B) will be shaped by data from the earlier parts.¹
• Enrollment is estimated at 499 participants¹, with primary completion estimated for 2031-03-31 and study completion estimated for 2032-03-31¹.